医药行业周报：赛诺菲/再生元IL-33单抗在华获批临床，针对慢性鼻窦炎

Industry Investment Rating - The report maintains a positive outlook on the pharmaceutical industry [1] - Sub-industry ratings: Chemical Pharmaceuticals (No Rating), Traditional Chinese Medicine Production (No Rating), Biopharmaceuticals II (Neutral), Other Medical and Healthcare (Neutral) [2] Core Views - The pharmaceutical sector underperformed the CSI 300 Index by 0.42 percentage points on January 15, 2025, ranking 28th among the 31 Shenwan sub-industries [4] - Pharmaceutical distribution (+0.12%), other biological products (-0.62%), and medical consumables (-0.87%) were the top-performing sub-sectors, while offline pharmacies (-2.11%), medical R&D outsourcing (-1.99%), and in vitro diagnostics (-1.46%) lagged behind [4] - Top gainers: LuKang Pharmaceutical (+4.35%), North China Pharmaceutical (+3.98%), Guofa Co., Ltd. (+3.74%) [4] - Top decliners: Kangwei Century (-18.74%), Saifen Technology (-13.08%), Jiudian Pharmaceutical (-9.86%) [4] Industry News - Sanofi's IL-33 monoclonal antibody, Itepekimab, received clinical approval in China for treating chronic rhinosinusitis without nasal polyps (CRSsNP) [5] - Itepekimab, developed in collaboration with Regeneron, has previously received multiple clinical trial approvals in China for non-cystic fibrosis bronchiectasis (NCFB) and moderate to severe chronic obstructive pulmonary disease (COPD) [5] Company News - Nuotai Biotech (688076) passed the FDA's cGMP on-site inspection at its Lianyungang production base [5] - Wanbangde (002082) expects 2024 net profit attributable to the parent company to be 65-90 million yuan, a year-on-year increase of 32.09%-82.89% [5] - Tebao Biotech (688278) forecasts 2024 net profit attributable to the parent company at 810-840 million yuan, up 45.83%-51.23% year-on-year [6] - Xiangxue Pharmaceutical (300147) anticipates a 2024 net loss of 599.61-862.43 million yuan, a year-on-year decrease of 54.15%-121.73% [6] Related Research Reports - Significant improvement in medical equipment bidding, optimistic about investment opportunities in domestic equipment companies (2025.1.6-2025.1.12) [7] - MaaT Pharma's small molecule innovative therapy succeeds in Phase III clinical trials [7] - Sanofi's Isatuximab approved in China for treating multiple myeloma [7]